LUPIN \u2014 Recent Activity

Update: BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 Billion; Shares Jump

(Updates with share price movement in headline and last paragraph). BioMarin Pharmaceutical (BMRN

Click to open →

BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 billion

BioMarin Pharmaceutical (BMRN) has agreed to acquire Amicus Therapeutics (FOLD) for $14.50 per share

Click to open →

Lupin Ltd (BOM:500257) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth ...

Lupin Ltd (BOM:500257) reports robust financial performance with significant US market growth and strategic expansions in Europe and emerging markets.

Click to open →

India's Lupin posts surge in quarterly profit on strong respiratory drugs demand

(Reuters) -Indian drugmaker Lupin posted a 73.3% jump in second-quarter profit on Thursday, driven by strong demand for its respiratory drugs.

Click to open →

India advances anti-dumping probe into tuberculosis drug imports from China, Thailand

NEW DELHI (Reuters) -India on Monday advanced an anti-dumping investigation into imports from China and Thailand of Ethambutol Hydrochloride, an active pharmaceutical ingredient used in anti-

Click to open →

Gilead Resolves Patent Litigations for HIV Treatment Biktarvy

Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.

Click to open →

Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump

Gilead stock popped Monday after the biotech giant said it signed deals with three generic drugmakers to delay their Biktarvy copycats.

Click to open →

Gilead stock rises after settling Biktarvy patent disputes

Investing.com -- Gilead Sciences Inc. (NASDAQ:GILD) stock rose 4.5% Monday after the company announced it had settled patent disputes with multiple generic drugmakers over its HIV treatment Biktarvy.

Click to open →

ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is among the fastest growing small cap stocks to buy. Lupin Inc., a leading player in the healthcare sector, sent a Paragraph IV certification notice to ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on August 13, 2025, outlining that Lupin has submitted an Abbreviated New Drug Application (ANDA) to the FDA for approval of […]

Click to open →

Catalyst Pharmaceuticals, Inc. (CPRX) Secures FIRDAPSE Market Exclusivity Until 2035

We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Catalyst Pharmaceuticals, Inc. is placed sixth among them. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a commercial-stage biopharmaceutical company specializing in treatments for rare and difficult-to-treat diseases. Its key products include FIRDAPSE (amifampridine), Fycompa, Ruzurgi, and AGAMREE, targeting neurological and […]

Click to open →